JMKX003002 / Shanghai Jeyou Pharmaceutical - LARVOL DELTA

Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JMKX003002 in Chinese healthy participants: a randomized, double-blind, placebo-controlled, single- and multiple-ascending dose, and food-effect phase I clinical trial. (PubMed, Ann Med) - P1 | "Chinese Clinical Trial Registry (ChiCTR2300070473). Registered on April 13, 2023; prospectively registered."

Clinical • Journal • P1 data • PK/PD data • Metabolic Disorders • Nephrology • Renal Disease

Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia (clinicaltrials.gov) - P2 | N=50 | Recruiting | Sponsor: Jemincare | Not yet recruiting ➔ Recruiting

Enrollment open • Chronic Kidney Disease • Metabolic Disorders • Nephrology • Renal Disease

Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia (clinicaltrials.gov) - P2 | N=50 | Not yet recruiting | Sponsor: Jemincare

New P2 trial • Chronic Kidney Disease • Metabolic Disorders • Nephrology • Renal Disease

Safety, Tolerability of JMKX003002 in Phase 1 Study in Healthy Subjects (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Jemincare

New P1 trial